Global Non-alcoholic steatohepatitis (NASH) Market Size, Trends, Competitive, Historical & Forecast Analysis to 2022-2028.
Non-alcoholic steatohepatitis (NASH) is a type of liver disease in which fat builds up in the liver of people who drink little or no alcohol. This causes inflammation of the liver and damage to the cells in the liver; it is a part of a group of conditions called NAFLD (non-alcoholic fatty liver disease). Non-alcoholic steatohepatitis (NASH) can get worse and cause scarring of the liver, which leads to cirrhosis and liver failure. People with nonalcoholic steatohepatitis are at an increased risk of spreading liver cancer. It is more common in middle-aged adults, especially in those who are overweight or obese or who have diabetes or high levels of cholesterol and triglycerides (a type of fat) in the blood.
Furthermore, obesity, high cholesterol, high triglycerides, metabolic syndrome, insulin resistance, and type 2 diabetes are some causes that helps to foster the growth of the non-alcoholic steatohepatitis (NASH) market. Nonalcoholic steatohepatitis (NASH) is a clinicopathological syndrome caused by genetic, environmental, and metabolic stress-related factors and clinically manifested as fat accumulation in hepatocytes. Specifically, this accumulation exceeds 5% of hepatic wet weight or changes in the fatty content took place in over 1/3 of hepatocytes per unit area even though the overconsumption of alcohol can be expressly excluded.
In the changing modern times, the mindset of the people is also changing, and this is also changing the preferences of the people such as eating processed food which leads to various health conditions like obesity, fatty liver and others. Many new diseases are arising due to various reasons like, liver disease, obesity, high cholesterol, high triglycerides, metabolic syndrome, insulin resistance, and type 2 diabetes are some diseases that may increase the risk of developing non-alcoholic steatohepatitis (NASH). Such as, estimated that there were 18.2 million people in the U.S. living with T2DM and NAFLD, of which 6.4 million had NASH. Twenty-year costs for NAFLD in these patients were $55.8 billion. Over the next 20 years, NASH with T2DM will account for 65,000 transplants, 1.37 million cardiovascular-related deaths, and 812,000 liver-related deaths.
The rising presence of non-alcoholic Steatohepatitis (NASH) along with the growing requirement for effective diagnostic tools is also driving the growth of the global non-alcoholic Steatohepatitis biomarkers market. Many pharmaceutical and research industries are working on the development of new drugs and treatments for NASH, and the number of research stations is increasing day by day due to funding provided by the government and non-government organizations. Industry participants are more looking into the availability of cost-effective solutions for NASH and thereby increasing R&D activities for the development of novel drug delivery and technologies. However, a lack of awareness and a greater number of people with undiagnosed disease conditions are anticipated to restrict the market growth of the non-alcoholic steatohepatitis biomarkers market. Moreover, in spite of that, the significant increase in the development of novel biomarkers is expected to generate huge opportunities for the further growth of the global non-alcoholic steatohepatitis market.
North America is expected to witness significant growth in the global non-alcoholic steatohepatitis market due to the increasing prevalence of non-alcoholic fatty liver disease in this region. Non-alcoholic fatty liver disease (steatohepatitis) is considered the most common form of chronic liver disease. As per Science Daily, 47% of the adult population in the United States may suffer from obesity by 2030, as compared to 37.7% in 2014. This represents an estimated 25% increase in obesity, by 2030. According to Science Daily, on the economic impact of the disease. The rising number of overweight patients in this region is also supplementing the growth of the non-alcoholic steatohepatitis market. In this region, the non-alcoholic fatty liver disease (NAFLD) affects about 100 million every year, and the cost of the disease impacting the U.S. healthcare system is nearly 32 USD billion annually. Europe is expected to witness a positive growth in the global non-alcoholic steatohepatitis market owing to the increasing cases of non-alcoholic steatohepatitis in this region.
There is no major trend available in the market as there is no approved treatment for NAFLD/NASH at global level and this could also limit physician motivation to put patients through the burden of a diagnosis. Thus, due to the lack of treatment options, standard of care involves only lifestyle interventions such as weight loss, exercise, diet, abstinence from alcohol to address the close relationship between NAFLD/NASH and metabolic syndrome. With the exciting recent developments in NAFLD/NASH clinical trials many companies have started to develop new drugs in which with multiple drugs currently in Phase III trials and many more in the global pipeline.
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2028|
|Market Size in 2021:||USD XXX Million|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2028:||USD XXX Million|
|Tables, Charts & Figures:||175|
|NASH Companies||Allergan plc. (Tobira Therapeutics), Cadila Healthcare Limited, Conatus Pharmaceuticals Inc., Galmed Pharmaceuticals Ltd, Gemphire Therapeutics Inc., Genfit SA, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Novartis International AG, Shire Plc.|
|Segments Covered||By Disease cause, By Drug Type|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|
Middle East and Africa